Antibody concentrations to vaccine-preventable diseases decline following BMT and an optimal schedule for vaccination after transplant has not been established. We examined antibody responses to tetanus toxoid (TT) and Haemophilus influenzae type b-conjugate (HIB) vaccines of BMT patients immunized at 6, 12 and 24 months (6 month group, n = 21) and compared them to those previously reported for patients immunized at 3, 6, 12 and 24 months (3 month group, n = 74) or at 12 and 24 months (12 month group, n = 17) following transplantation. Geometric mean total anti-HIB and IgG anti-TT concentrations were significantly higher after the 12 month dose in the 3 and 6 month immunization groups compared to the group who received their first dose at 12 months. Although HIB antibody concentrations were higher in the 3 month and 6 month groups 12 to 24 months after BMT, the proportion of patients with protective levels was not significantly different from the proportion protected in the 12 month group. Following the 24 month immunizations, geometric mean antibody concentrations to HIB and TT were similar for all three immunization groups. The proportion of patients in each group with protective levels of HIB antibody after the 24 month dose was у80%. A two dose schedule of HIB and TT vaccines at 12 and 24 months after BMT should afford protection. Keywords: immunizations, active; vaccines, conjugate; vaccines, protein; bone marrow transplantation
of transplant or the presence and treatment of graft-versushost disease, all transplant recipients are at increased risk for infectious complications from a wide range of pathogens following BMT. 4, 5 Encapsulated bacteria, including Haemophilus influenzae type b (HIB) and Streptococcus pneumoniae, are causes of late (у100 days post BMT) infections. 3, [5] [6] [7] One potential approach to reduce the incidence of late bacterial infections is through immunization. Poor responses of patients to pure polysaccharide vaccines have limited their usefulness in the BMT setting. [7] [8] [9] In contrast, polysaccharide-conjugate vaccines which link a protein carrier to bacterial capsular polysaccharides elicit T cell-mediated responses and are more immunogenic. Immunization of transplant recipients with HIB-conjugate vaccine 18-24 months following BMT has produced reliable antibody responses. 10, 11 A booster response to a second dose of HIB-conjugate vaccine administered late after transplant has also been demonstrated. 11 More recently, we have shown that immunization of allogeneic transplant donors and autologous transplant patients with HIB-conjugate vaccine before marrow harvest significantly enhanced antibody responses of patients who received additional doses after transplantation. 9, 12 Donor immunization, however, may not always be feasible. In unrelated donor transplantation, donors are anonymous and thus cannot be immunized before transplantation. In addition, donor immunization may not be a practical approach for all vaccines given the low frequency with which the vaccine-preventable disease occurs following BMT. An optimal schedule for administering immunizations after BMT and achieving early protection has not yet been established. In this report, the effect of three different immunization schedules on antibody responses to HIBconjugate and tetanus toxoid vaccines administered during the first 2 years following BMT are compared. We have previously published results for allogeneic and autologous transplant BMT patients immunized starting at 3 months or as late as 12 months after transplantation. 9, 11, 12 We now compare the antibody responses of these patients to those of patients immunized beginning at 6 months after transplant. Results from allogeneic and autologous transplant patients in each immunization group are combined as we have previously demonstrated no significant differences in antibody concentrations between allogeneic and autologous transplant patients immunized after transplant.
Patients and methods

Study populations
BMT patients older than 2 years of age who received a matched related allogeneic or autologous bone marrow transplantation for lymphoma, aplastic anemia or leukemia between April 1990 and August 1993 at Brigham and Women's, Children's and Beth Israel Hospitals in Boston, MA were recruited. Patients were conditioned for transplantation according to diagnosis and current protocols which included TBI and/or chemotherapy for allogeneic transplant patients and for autologous transplant patients TBI with marrows purged with anti-B1, B4 blocked ricin or 4-HC. [13] [14] [15] T cell depletion was performed using anti-CD5 monoclonal antibodies as previously described. 16 GVHD prophylaxis consisted of short-course methotrexate and cyclosporine until day 50 post transplant at which time it was tapered at the discretion of the attending physician. The diagnosis of GVHD was established clinically using standard criteria. 17 Patients enrolled at 3 months or at 12 months after transplant have been previously described in detail. 9, 11, 12 All investigations were approved by the Institutional Review Boards of the participating hospitals and informed written consent was obtained from all enrolled patients or their parents/guardians.
Immunization schedule
BMT patients were assigned to one of three immunization schedules depending upon the time of enrollment post BMT. Patients enrolled at 3 months (three month group) were immunized with 0.5 cc HIB-conjugate vaccine (HibTITER; Lederle-Praxis Biologicals Division, American Cyanamid, West Henrietta, NY, USA) and 0.5 cc of tetanus toxoid aluminum phosphate adsorbed vaccine (Wyeth Laboratories, Philadelphia, PA, USA) intramuscularly at 3, 6, 12 and 24 months post transplant. Patients enrolled at 6 months were immunized with HIB-conjugate and tetanus toxoid vaccines at 6, 12 and 24 months and patients enrolled at 12 months were immunized with both vaccines 12 and 24 months post transplant. Serum was obtained from each patient prior to the administration of vaccines and 3-6 weeks following the 24 month immunizations. Patients who had a follow-up visit between 12 and 24 months after transplant had an additional blood sample drawn. The 'post 12 month' sample was obtained a median of 9 weeks after the 12 month immunization (range 3-52 weeks). All sera were stored at Ϫ70°C until assayed.
Antibody assays
Total anti-HIB capsular antibody was measured by radioimmuno-assay (RIA) using a standard Food and Drug Administration protocol with tritiated polyribosylribitol phosphate (provided by Dr Porter Anderson, University of Rochester, NY, USA). The RIA was standardized using the Center for Biologic Research and Review standard serum pool with an assigned value of 70 g/ml. IgG anti-tetanus toxoid antibody was measured by enzyme-linked immunosorbent assay (ELISA). 18 Microtiter plates were coated with 2 g/ml tetanus toxoid (Massachusetts Public Health Laboratories, Jamaica Plain, MA, USA) and two-fold dilutions of sera were added starting at a 1:20 dilution. IgG antitetanus toxoid antibody was detected by goat anti-human IgG alkaline phosphatase conjugate (Caltag Laboratories, South San Francisco, CA, USA). The ELISA was standardized using a reference plasma pool with an assigned IgG anti-tetanus toxoid antibody concentration of 56.1 g/ml.
Statistics
Antibody concentrations were transformed to logarithms for statistical calculations. Antibody concentrations below the limit of assay sensitivity were assigned values of one half the lower limit. The lower limit of detection of total anti-HIB antibody was 0.125 g/ml. All patients had IgG tetanus toxoid antibody concentrations above the limit of assay sensitivity. Three-way comparisons of geometric mean antibody concentrations were performed by the Newman Keuls test for parametric analysis and by the Kruskal Wallis test for non-parametric analysis. The frequency of individuals within each immunization group with protective concentrations of total anti-HIB antibody at various timepoints after transplant were compared by Fisher exact test.
Results
Patient population
Clinical characteristics of evaluable BMT patients within each immunization group are shown in Table 1 . Evaluable patients are defined as those who survived without relapse until receipt of at least their initial immunizations. Individuals who missed subsequent immunizations, relapsed, or died after their initial immunizations were excluded in data analyses after the time these events occurred. Seventy-four patients were enrolled at 3 months, 21 patients were enrolled at 6 months and 17 patients were enrolled at 12 months. The number of patients within each group evaluable at subsequent time points is shown in Table 1 .
Antibody responses to HIB-conjugate vaccine
BMT patients initially immunized 3 or 6 months after transplant had higher geometric mean total anti-HIB antibody concentrations at 12 months, post 12 months, and at 24 months compared to patients who received their initial immunizations at 12 months (ie 12 month group) ( Figure  1a ). Geometric mean total anti-HIB antibody concentrations were not significantly different for patients in the 3 month immunization group compared to those achieved in patients in the 6 month immunization group at any of the measured time-points. Following the 12 month dose of HIB-conjugate vaccine, patients in the 3 month immunization group and those in the 6 month immunization group had significant increases in geometric mean total anti-HIB antibody from 0.843 g/ml to 2.62 g/ml (P = 0.006) and from 0.412 g/ml to 1.72 g/ml (P = 0.011) respectively (Table 2) . In contrast, patients in the 12 month immuni- zation group did not have a significant increase in total anti-HIB antibody following their first vaccine dose (0.152 g/ml to 0.273 g/ml, P Ͼ 0.05). At 24 months after transplant, all three immunization groups had significant responses to the 24 month dose (Figure 1 ). Geometric mean total anti-HIB antibody concentrations measured after the 24 month immunization were similar between the three groups (15.1 g/ml, 18.7 g/ml and 14.8 g/ml, respectively).
To determine whether the three immunization schedules differed in their potential to prevent clinical HIB disease, the number of patients in each immunization group who achieved 'protective' HIB antibody concentrations were compared. A concentration of total anti-HIB antibody у1.00 g/ml as measured by RIA is considered to be predictive of long-term protection in a vaccinated population. 19 The proportions of patients with protective levels at 12 months, post 12 months, 24 months and post 24 months were not significantly different between the immunization groups. Following the 12 month dose of HIB-conjugate vaccine, 53, 46 and 27% of patients in the 3 month, 6 month, and 12 month immunization groups had protective levels. By 24 months, the proportion of patients with protective concentrations declined in each group, but increased to 80, 89 and 80%, respectively, after the 24 month dose.
Antibody responses to tetanus toxoid vaccine
Similar to the results with HIB-conjugate vaccine, geometric mean IgG anti-tetanus toxoid antibody concentrations were higher in patients immunized initially at 3 and 6 months compared to those immunized starting at 12 months after transplant (Figure 1b) . Patients in the 3 month immunization group had significantly higher geometric mean IgG anti-tetanus antibody concentrations at 12 months, post 12 months and at 24 months compared to patients in the 12 month immunization group. Patients in the 6 month immunization group had significantly higher geometric mean IgG anti-tetanus antibody levels post 12 months and at 24 months compared to patients in the 12 month immunized group (Table 2) . Although there were no significant differences in geometric mean IgG anti-tetanus toxoid antibody concentrations for patients in the 3 month immunization group as compared to those in the 6 month immunization group, patients in the 6 month immunization group had a significant decline in antibody between 6 and 12 months with geometric mean IgG anti-tetanus toxoid antibody concentrations of 25.2 g/ml at 6 months and 7.89 g/ml at 12 months (P = 0.001) (Figure 1b) . A decline in tetanus toxoid antibody did not occur in the 3 month immunization group (26.9 g/ml at 6 months and 26.6 g/ml at 12 months). Following the 12 month vaccine dose, geometric mean IgG anti-tetanus toxoid antibody concentrations increased significantly in the 3 month and 6 month immunization groups from 26.6 to 143 g/ml (P = 0.005) and from 7.89 to 81.9 g/ml (P = 0.004), respectively ( Figure 1b) . Patients who received tetanus toxoid vaccine beginning at 12 months after BMT had no significant increase in geometric mean IgG anti-tetanus toxoid antibody concentration following the 12 month dose (4.10 to 4.69 g/ml, P Ͼ 0.05) ( Table 2 ). Similar to HIB, significant responses were seen following the 24 month dose of tetanus toxoid vaccine for each group with geometric mean IgG anti-tetanus toxoid antibody concentrations of 260 g/ml, 272 g/ml and 195 g/ml for the 3 month, 6 month and 12 month immunization groups, respectively. The presumed protective level for tetanus toxoid antibody is у0.01 IU/ml which was equivalent to у0.43 g/ml in our IgG tetanus toxoid ELISA. 11 All patients in each immunization group had protective IgG anti-tetanus toxoid concentrations before their respective initial immunization and у90% of patients in all three immunization groups maintained protective concentrations over the study period.
Factors influencing antibody concentrations following BMT
To examine whether variables other than the immunization schedule were significantly associated with total HIB or IgG tetanus toxoid antibody concentrations, the following factors were analyzed at 12, post 12, 24 and post 24 months transplantation by multiple linear stepwise regression analysis: immunization group, underlying diagnosis, type of transplant (allogeneic, autologous), sex, donor age, recipient age, T cell depletion, TBI, ex vivo marrow conditioning, receipt of intravenous immune globulin (IVIG) within 30 days of immunization, GVHD at the time of immunization and treatment for GVHD within 30 days of immunization. Because donor age and recipient age were highly correlated in our study population (r = 0.94), donor age was entered into the regression model when both variables were significant (for autologous transplant patients, age was entered in both the recipient and donor columns).
Being in the 12 month immunization group was indepen-dently associated with lower total anti-HIB antibody concentrations at 12 months (P = 0.0005), post 12 months (P = 0.0005) and 24 months (P = 0.043), and with lower IgG anti-tetanus toxoid antibody concentrations post 12 months (P = 0.0001) and 24 months (P = 0.0001) after transplantation. Younger donor age was independently significantly associated with higher total anti-HIB antibody concentrations at 12 months (P = 0.038), post 12 months (P = 0.002), 24 months (P = 0.006), post 24 months (P = 0.017), and with higher IgG anti-tetanus toxoid antibody concentrations post 12 months (P = 0.001), 24 months (P = 0.001) and post 24 months (P = 0.0001). T cell depletion was independently associated with lower total anti-HIB antibody (P = 0.0005) and lower IgG anti-tetanus toxoid antibody (P = 0.01) concentrations post 24 months transplantation.
Discussion
Immunization of BMT patients is recommended as antibody concentrations to vaccine-preventable diseases decline following transplantation. Previous studies have shown that multiple doses of vaccines administered after transplant result in higher concentrations of antibody and prime for increased responses to additional doses. 10, 11, 20 The data in this study comparing early (3 months), intermediate (6 months) and late (12 months) immunization schedules further define antibody responses to vaccines administered after transplantation. Bone marrow transplant patients who received multiple doses of HIB and tetanus toxoid vaccines beginning at 3 months or 6 months after transplant had significantly higher HIB and tetanus toxoid antibody concentrations 12 to 24 months after transplant compared to patients initially immunized at 12 months. Patients in the 3 month and 6 month immunization groups had significant responses to the 12 month HIB-conjugate and tetanus toxoid vaccine doses in contrast to patients in the 12 month immunization group who had minimal antibody responses to the 12 month immunizations. However, specific antibody concentrations declined in all three immunization groups by 24 months after transplant. Following the 24 month immunizations, geometric mean antibody concentrations to HIB and tetanus toxoid were similar whether patients had received one, two, or three previous doses.
These results suggest that both the number of doses and timing of the doses after transplant determine responses to vaccines. In addition to the timing of vaccine administration, important considerations in selecting an optimal immunization schedule include the likelihood of complications from a vaccine-preventable disease after BMT, the time period post transplant when protection is most needed, and the effectiveness of an immunization approach. Although the earlier doses of HIB-conjugate vaccine at 3 and/or 6 months resulted in geometric mean total anti-HIB antibody concentrations of approximately 1 g/ml following the 12 month immunization, the clinical impact of these earlier schedules would be minimal. Most patients would not be protected by this response as antibody concentrations decline between 12 and 24 months after transplant. In our study, less than half of the patients in the 3 month and 6 month groups had protective HIB antibody concentrations by 24 months after transplant. Other investigators have advocated an early immunization approach with a single dose of HIB-conjugate vaccine at 6 months after transplant, accepting a post immunization geometric mean IgG anti-HIB antibody concentration of 1.62 g/ml as signifying an adequate response. 21 We would recommend that a more effective approach would be a multiple dose schedule that results in geometric mean antibody concentrations comparable to the concentrations of 10-19 g/ml achieved in infants after a three-dose series with documented efficacy in reducing invasive disease. 22, 23 Following the 24 month dose of HIB vaccine, geometric mean antibody concentrations for the 3 month, 6 month and 12 month immunization groups ranged from 15 to 19 g/ml. As HIB disease occurs infrequently after transplant, two doses of HIB-conjugate vaccine at 12 and 24 months is a reasonable approach. Whether earlier protection could be achieved with an additional dose at 14 months after transplant needs to be defined. A two-dose schedule of tetanus toxoid vaccine administered at 12 and 24 months after BMT should also be adequate to maintain protective antibody concentrations as early protection against tetanus is not urgent. All patients in our study had protective concentrations of tetanus toxoid antibody prior to immunization and over 90% of patients in each immunization group maintained protective concentrations during the first 2 years after transplant. Other investigators have shown multiple dose schedules of tetanus toxoid to be immunogenic following allogeneic BMT. In a study by Parkkali et al, 24 anti-tetanus toxoid antibody concentrations elicited in allogeneic BMT patients following immunization at 6, 8 and 14 months were similar to those produced in patients immunized at 18, 20 and 24 months. Ninety percent of patients immunized initially at 6 months and 70% of patients immunized initially at 18 months had protective concentrations prior to immunization. Our results are also similar to the anti-tetanus toxoid antibody concentrations elicited in allogeneic transplant patients immunized with three doses of tetanus toxoid vaccine between 12 and 36 months after transplant. 20 Other variables that had significant effects on HIB and tetanus toxoid antibody concentrations were donor age and T cell depletion. Younger donor age was associated with increased total HIB and IgG anti-tetanus toxoid antibody concentrations post 12 months and at 24 months. In contrast, T cell depletion was significantly associated with lower antibody concentrations to both vaccines following the 24 month immunizations. The effects of these variables on HIB and tetanus toxoid antibody concentrations have been previously published by our group. 9, 12 A limitation of our study is that patients were assigned, not randomized, to an immunization schedule based on the time they were approached following BMT. Although the clinical characteristics of patients enrolled in the study were similar between the groups, other variables may have differed that may have affected antibody responses. In addition, not all eligible patients were approached for enrollment in the study and therefore our results may not be representative for similar patients undergoing BMT. Finally, the number of patients evaluable over the course of the study limits our ability to examine the effects of the conditioning regimen, marrow purging, receipt of IVIG, or presence and treatment of GVHD on antibody responses.
Although HIB is an infrequent complication following transplantation, Streptococcus pneumoniae is a more common pathogen. 4, 6, 25, 26 The results of these studies with HIBconjugate vaccine are useful in designing effective schedules for pneumococcal immunization. Previous studies have shown that polyvalent pneumococcal polysaccharide vaccines are not immunogenic in transplant recipients even when administered as late as 24 months after transplant, and multiple doses do not elicit booster responses. 7, 11, 27 Pneumococcal-conjugate vaccines which elicit T celldependent responses and prime for increased responses to capsular polysaccharides are now in efficacy trials for infants. 28, 29 Since pneumococcal disease may occur as early as 6 months after BMT, strategies to elicit high concentrations of pneumococcal antibody before 12 months may benefit transplant patients. We are currently studying the effect of early recipient immunization with multiple doses of pneumococcal-conjugate vaccine following transplantation with or without donor immunization in randomized trials.
